Cargando…
Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug
Dipeptidyl peptidase4 (DPP4) inhibitors such as gemigliptin are anti-diabetic drugs elevating plasma concentration of incretins such as GLP-1. In addition to the DPP4 inhibition, gemigliptin might directly improve the functions of vessels under pathological conditions. To test this hypothesis, we in...
Autores principales: | Kim, Hae Jin, Baek, Eun Bok, Kim, Sung Joon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Physiological Society and The Korean Society of Pharmacology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205934/ https://www.ncbi.nlm.nih.gov/pubmed/30402032 http://dx.doi.org/10.4196/kjpp.2018.22.6.713 |
Ejemplares similares
-
Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
por: Nam, Dae-Hwan, et al.
Publicado: (2019) -
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016) -
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
por: Choi, Seung Hee, et al.
Publicado: (2017) -
The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries
por: Stanley, Christopher P., et al.
Publicado: (2016) -
Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells
por: Choi, Soon-Youn, et al.
Publicado: (2017)